mRNA-2752 + Durvalumab
Phase 1CompletedDevelopment Stage
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Nov 27, 2018 → Aug 1, 2025
About mRNA-2752 + Durvalumab
mRNA-2752 + Durvalumab is a phase 1 stage product being developed by AstraZeneca for Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03739931. Target conditions include Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03739931 | Phase 1 | Completed |
Competing Products
6 competing products in Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E3810 + E3810 + Teprenone | Eisai | Phase 2/3 | 65 |
| Rabeprazole + Rabeprazole | Eisai | Phase 2/3 | 65 |
| LDE225 + BKM120 | Novartis | Phase 1 | 33 |
| Carbidopa/levodopa/entacapone | Novartis | Approved | 85 |
| ETC-1002 | Esperion Therapeutics | Phase 1 | 28 |
| AUTO CAR T cell therapy | Autolus Therapeutics | Phase 2 | 44 |